REGENXBIO Shares Decline 17% After FDA Imposed Clinical Holds On Gene Therapy Programs

Core Viewpoint - REGENXBIO Inc. experienced a significant stock decline of 17.75% following the FDA's clinical hold on two investigational gene therapy programs [1] Group 1: Stock Performance - The company's shares closed at $11.03 after a drop of $2.38 [1] - The stock opened at $9.60, down from the previous close of $13.41, and traded between $9.51 and $11.50 during the session [3] - Trading volume reached approximately 3.88 million shares, significantly higher than the average volume of about 690,186 shares [3] Group 2: FDA Clinical Hold - The FDA imposed a clinical hold on the RGX-111 program, which was under investigation for treating MPS I or Hurler syndrome, due to a preliminary review of a neoplasm case involving a central nervous system tumor in a trial participant [2] - This hold has raised concerns regarding the safety and viability of the gene therapy programs [2] Group 3: Historical Stock Range - REGENXBIO's stock has fluctuated within a 52-week range of $5.03 to $16.19 [4]